ReviewUpdates in surgery2018
Gastroesophageal reflux and Barrett's esophagus: a pathway to esophageal adenocarcinoma.
Review in Updates in surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 39 citations in OpenAlex.
- Genetically Predicted Sarcopenia Traits and the Risk of Barrett's Esophagus.Food science & nutrition · 2025Article
- AI-Driven Risk Prediction Tool (TSP-9) Informs Risk-Aligned Care for Patients with Barrett's Esophagus.Diagnostics (Basel, Switzerland) · 2025Article
- A safety and effectiveness evaluation of refluxstop in the treatment of acid reflux comparing large and small hiatal hernia groups: results from 99 patients in Switzerland with up to 4-years follow-up.Hernia : the journal of hernias and abdominal wall surgery · 2025Article
- Exploring the genetic link between gastroesophageal reflux disease and pancreatic cancer: insights from Mendelian randomization.BMC cancer · 2025Article
- Novel perspectives on the link between obesity and cancer risk: from mechanisms to clinical implications.Frontiers of medicine · 2024Review
- Association between four insulin resistance surrogates and the risk of esophageal cancer: a prospective cohort study using the UK Biobank.Journal of cancer research and clinical oncology · 2024Article
- Translating Molecular Biology Discoveries to Develop Targeted Cancer Interception in Barrett's Esophagus.International journal of molecular sciences · 2023Review
- Gastroesophageal reflux disease incidence among male patients with irritable bowel syndrome: A single-center cross-sectional study in southern Iran.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Causal association between dietary factors and esophageal diseases: A Mendelian randomization study.PloS one · 2023Article
- Molecular mechanism, regulation, and therapeutic targeting of the STAT3 signaling pathway in esophageal cancer (Review).International journal of oncology · 2022Article
- APE1 redox function is required for activation of Yes-associated protein 1 under reflux conditions in Barrett's-associated esophageal adenocarcinomas.Journal of experimental & clinical cancer research : CR · 2022Article
- Intestinal Stem Cell Marker ASCL2 is a Novel Prognostic Predictor in Esophageal Adenocarcinoma.Cureus · 2022Article
- IL-33 Participates in the Development of Esophageal Adenocarcinoma.Pathology oncology research : POR · 2022Article
- Self-Reported Gastrointestinal Symptoms Two To Four Years After Bariatric Surgery. A Cross-Sectional Study Comparing Roux-en-Y Gastric Bypass and Laparoscopic Sleeve Gastrectomy.Obesity surgery · 2021Article
- Tongue diagnosis indices for gastroesophageal reflux disease: A cross-sectional, case-controlled observational study.Medicine · 2020Observational
- Curcumin: A Potent Protectant against Esophageal and Gastric Disorders.International journal of molecular sciences · 2019Review
- Does anti-reflux surgery disrupt the pathway of Barrett's esophagus progression to cancer?Translational gastroenterology and hepatology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of esophageal adenocarcinoma (EAC) has increased significantly in Western countries. The rising prevalence of gastroesophageal reflux disease (GERD) and obesity has played a major role in the increasing numbers of EAC. Approximately 10-15% of patients with GERD will develop Barrett's esophagus (BE). This metaplastic transformation is due to the chronic injury produced by repeated reflux episodes and involves genetic mutations that can lead to a malignant transformation. Ultimately, the development of EAC is characterized by the sequence BE metaplasia-dysplasia-invasive carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.